Quantcast

Latest placebo Stories

2014-10-22 08:31:01

Results indicate Zalviso controlled moderate-to-severe acute pain following abdominal surgery better than placebo, with similar side effect profile REDWOOD CITY, Calif., Oct. 22, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that results from the IAP310 study have been published in Regional Anesthesia and Pain Medicine (RAPM), a peer-reviewed journal with broad, multidisciplinary readership. IAP310 was a randomized, placebo-controlled, Phase 3...

2014-10-15 20:22:42

Company to make OFEV available to IPF community within 10 days, along with comprehensive patient support resources RIDGEFIELD, Conn., Oct. 15, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved OFEV® (nintedanib) capsules for oral use for the treatment of idiopathic pulmonary fibrosis (IPF). Granted Breakthrough Therapy designation during its review by the FDA, OFEV, capsules for oral use, taken twice...

2014-10-14 08:33:40

MIAMI and NEW YORK, Oct. 14, 2014 /PRNewswire/ -- Noven Pharmaceuticals, Inc., today announced the publication of data on the effects of low-dose mesylate salt of paroxetine (LDMP), marketed as Brisdelle(® )(paroxetine) capsules, 7.5 mg, in the October 2014 issue of Menopause, the peer-reviewed, scientific journal of The North American Menopause Society (NAMS). The article, "Effects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of vasomotor symptoms associated...

2014-10-13 16:25:04

--Study Demonstrated Clinically Meaningful and Statistically Significant Improvement of Agitation in Patients with Alzheimer's Disease-- ALISO VIEJO, Calif., Oct. 13, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that results from the Phase II study evaluating AVP-923 for the treatment of agitation in patients with Alzheimer's disease were presented at the 2014 American Neurological Association Meeting. In this study utilizing the two-stage, sequential...

2014-10-10 12:24:47

WOODCLIFF LAKE, N.J. and SAN DIEGO, Oct. 10, 2014 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that a pooled analysis of the BLOOM and BLOSSOM pivotal, Phase 3 clinical trials of BELVIQ(®) (lorcaserin HCl) was published in the October issue of Postgraduate Medicine, a peer-reviewed medical journal for physicians. In the pooled analysis, BELVIQ 10 mg twice daily, as compared to placebo and both in conjunction with diet and exercise, was associated...

2014-10-08 16:26:39

Research conducted on slaughterhouse workers with chronic pain symptoms. AKRON, Ohio, Oct. 8, 2014 /PRNewswire/ -- Researchers at the National Research Centre for the Working Environment in Copenhagen, Denmark compared the effectiveness of Biofreeze(®) topical analgesic and a placebo gel on reducing chronic pain and symptoms of carpal tunnel syndrome in slaughterhouse workers. Compared to the placebo gel, Biofreeze Pain Reliever reduced hand/wrist pain by 31%. Carpal tunnel...

2014-10-02 00:21:35

-FREEDOM-1 study showed that ITCA 650 demonstrated positive results when added to standard oral diabetes medications. All endpoints were met regarding HbA1c and weight reductions, as well as the percent of patients treated to goal. Pre-specified sub-group analyses on HbA1c reductions over time also showed clinically and statistically significant impact across a wide spectrum of patients and background medications. Significant HbA1c reductions were observed over the 39 weeks ranging from a...

2014-10-01 08:33:14

FLORHAM PARK, N.J., Oct. 1, 2014 /PRNewswire/ -- Shionogi Inc., a global leader dedicated to women's health, will unveil four abstracts containing new analyses and safety and efficacy data from clinical trials of ospemifene (available in the U.S. marketplace as Osphena(®)) at the 25(th) Annual Meeting of The North American Menopause Society (NAMS) in Washington, DC on October 15-18, 2014. Osphena(®) (ospemifene) is approved for the treatment of moderate to severe dyspareunia, a symptom of...

2014-09-19 08:25:54

CORAL SPRINGS, Florida, September 19, 2014 /PRNewswire/ -- BioTech News Coverage: Progress made as biotech companies release latest developments, patents and results of studies and trials. Companies in focus are: GenSpera Inc. (OTC: GNSZ), Eli Lilly and Company (NYSE: LLY), Gilead Sciences Inc. (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA) GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for...

2014-09-17 08:29:26

- Phase 2 Clinical Results Show Positive Trends in Slowing Advancement of Disease - PALO ALTO, Calif., Sept. 17, 2014 /PRNewswire/ -- Neuraltus Pharmaceuticals, Inc. announced today that promising efficacy results of the Company's Phase 2 clinical program of NP001 for the treatment of amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease) are being highlighted today in an oral presentation at the inaugural Summit of the ALS Research Group, being held in Bloomington,...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.